ArticleKidney research and clinical practice2026
Remission of hematuria is associated with a better prognosis in immunoglobulin A nephropathy.
Article in Kidney research and clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe clinical significance of hematuria in immunoglobulin A nephropathy (IgAN) remains unclear. We defined remission of hematuria using stricter yet more intuitive criteria than those in previous studies and evaluated its association with prognosis in IgAN.
methodsThis retrospective, multicenter, observational study enrolled 403 patients with IgAN. Hematuria remission was defined as hematuria persisting for at least 3 months before and after diagnostic biopsy, followed by the absence of erythrocytes in four consecutive high-power field microscopic examinations at 3-4-month intervals. Clinical outcomes were compared between the hematuria remission (remission) and persistent hematuria (persistent) groups.
resultsThe mean annual rate of estimated glomerular filtration rate (eGFR) decline was lower in the remission group than in the persistent group (-1.51 ± 2.86 vs. -2.60 ± 3.18 mL/min/1.73 m2 /yr, p = 0.002). In the remission group, the mean annual rate of eGFR decline decreased after hematuria disappearance (from -1.28 ± 7.06 to 0.09 ± 0.29 mL/min/1.73 m2 /yr, p = 0.02). The proportion of ≥50% decline in eGFR from baseline was also lower in the remission group (p = 0.03). Hematuria remission was an independent prognostic factor of ≥50% decline in eGFR from baseline (hazard ratio, 0.55; 95% confidence interval, 0.33-0.99). However, progression to end-stage kidney disease did not differ significantly between two groups (p = 0.08). Similar results were obtained for propensity score matching.
conclusionHematuria remission, defined by the newly proposed stricter criteria, could be a potent prognostic factor in IgAN with straightforward applicability in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.